Niclosamide combined to Azacitidine to target TP53-mutated MDS/AML cells. Maslah N, Rety S, Bonnamy M, Aguinaga L, et al. Leukemia 2024;38:1630-1633.

Read + Share

Amedeo Smart

Independent Medical Education

Maslah N, Rety S, Bonnamy M, Aguinaga L, et al. Niclosamide combined to Azacitidine to target TP53-mutated MDS/AML cells. Leukemia 2024;38:1630-1633.
PMID: 38777834